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Serendipity: decitabine monotherapy induced com-
plete molecular response in a 77-year-old patient
with acute promyelocytic leukemia
Acute promyelocytic leukemia (APL) is an uncommon
but very aggressive subtype of acute myeloid leukemia
(AML), accounting for 10-15% of adult AML with 600-
800 new cases per year in the United States.1,2 Over 95%
of cases involve translocation t(15;17)(q22;q21), which
results in the promyelocytic leukemia retinoic acid recep-
tor alpha (PML-RARa) rearrangement and fusion
protein.3Most of the remaining APL cases harbor a fusion
protein involving RARa and another partner.4 The 
PML-RARa fusion gene initiates APL by blocking differ-
entiation and increasing self-renewal and proliferation of
leukemic progenitor cells. 
In the 1970s, outcomes in APL were dismal.
Anthracycline-based regimens were used, producing
long-term survival rates of 15-25%.1 This changed drasti-
cally with the introduction of all-trans retinoic acid
(ATRA) and arsenic trioxide (ATO) which both target the
PML-RARa fusion. With modern ATRA and ATO thera-
py, long-term survival rates approach 95%, in many cases
without cytotoxic therapy.5
Herein, we present a case of an APL patient with the
typical PML-RARa fusion, but atypical morphology and
immunophenotype, who unexpectedly achieved mor-
phological and molecular remission after treatment with
single agent decitabine.
A 77-year-old female with atrial fibrillation and hyper-
tension presented with two months of progressive
fatigue and oral ulcers. Family history was significant for
a brain tumor (classification unknown) in her mother,
and breast cancer in two of her daughters. She consumed
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Figure 1. Diagnosis marrow morphologic evaluation and
flow cytometry. Panel A: The bone marrow was hypercellu-
lar with >90% cellularity and 63% blasts. There was a pre-
dominance of atypical mononuclear cells with monocytoid
features and some atypical promyelocytes. Top left: aspirate
with Wright Stain 100x original magnification. Top right:
aspirate with myeloperoxidase stain 100x original magnifi-
cation. Panel B: Characteristic microgranular/hypogranular
APL flow cytometry phenotype of the patient. Flow cytometry
of the patient’s bone marrow aspirate at diagnosis is depict-
ed. The blasts had moderate CD45 expression and reduced
side scatter, shown in a “blast” gate (upper left panel) and
encompassing 79% of total cellular events. The blasts were
positive for CD33 (bright), CD34 (82%, blue), CD117, CD2
(dim), CD13, and CD64 (dim). The blasts were negative for
HLA-DR and CD11b. The blasts were also negative for CD14,
CD123, CD19, and CD56 (not shown).
A
B
alcohol socially, never smoked, and had no history of
illicit drug use. Physical exam including vital signs were
normal on presentation, and the patient had no bruises,
petechiae, or lymphadenopathy.
Complete blood counts revealed WBC 5600/mL, 69%
blasts, hemoglobin 9.3 g/dL, and platelets 24000/mL.
Coagulation panel revealed elevated PT (14.2 seconds)
and INR (1.31), and normal PTT (24.6 seconds) and fib-
rinogen (200 mg/dL). Comprehensive metabolic panel
was normal. Serum LDH was 258 units/L and uric acid
was 6.3 mg/dL. Peripheral smear morphology revealed a
large blast population with no promyelocytes or Auer
rods. Bone marrow biopsy revealed AML with matura-
tion (Figure 1A). Flow cytometry identified 79% blasts
characterized by co-expression of CD33, CD34, CD117,
CD13, CD2 (dim), CD64 (dim) and negative expression
of HLA-DR, CD14, CD11b, CD19, CD56, and CD123
(Figure 1B). Cytogenetics revealed a t(15;17) rearrange-
ment which was subsequently confirmed by fluorescence
in situ hybridization (FISH) as a PML-RARa fusion in
91.5% of cells and 100% of transcripts by quantitative
reverse transcriptase polymerase chain reaction (RT-
PCR). FLT3-ITD testing was positive by standard meth-
ods. While the laboratory‘s protocol is to perform upfront
FISH for 7 probes (including PML-RARa) on all suspected
cases of AML, only routine cytogenetics was initially
requested in this case.  As the morphology and flow cyto-
metric findings were not typical for APL, it was originally
reported as AML with maturation.  Cytogenetic studies
demonstrating a t(15;17) and confirmatory FISH/RT-PCR
were reported in the electronic medical record approxi-
mately one week after the initial diagnosis of AML with
maturation was reported, but did not come to immediate
clinical attention.  
Given the patient’s advanced age and presumed diag-
nosis of AML, she was treated with a 10-day course of
decitabine. Her leukocyte count did not increase during
treatment, as might be typical of differentiation syn-
drome. She developed mild coagulopathy evidenced by
elevated INR (peak 1.70), but she had no evidence of
bleeding and the fibrinogen and D-Dimer remained nor-
mal throughout. Her hospital course was complicated by
multifocal embolic infarcts attributed to atrial fibrillation,
resulting in expressive aphasia and gait abnormalities.
The patient was discharged to inpatient rehabilitation on
hospital day 22, and two subsequent cycles of 5-day
decitabine consolidation were administered by her local
oncologist. 
At her first follow-up appointment at our institution,
the pre-treatment cytogenetics were reviewed and her
diagnosis was amended to APL. A restaging bone mar-
row biopsy at that time confirmed achievement of com-
plete molecular remission (Figure 2) with cytogenetic
remission and negative RT-PCR.
Given her complete remission, the patient was treated
with four cycles of ATRA and ATO consolidation per
LoCocco protocol.5 She has experienced significant neu-
rological recovery with mild right facial weakness,
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Figure 2. Day 30 marrow morphologic evaluation. D30 Marrow morphologic evaluation. The bone marrow was normocellular for age and showed trilineage
hematopoiesis with an erythroid predominance and no increased blasts. Top left: core 2x original magnification. Top right: core 10x original magnification,
Bottom row: bone marrow aspirate 40x original magnification. 
expressive aphasia, and wide-based gait. She remains
independent for ADLs and IADLs. She is now 1,035 days
from diagnosis in both morphologic and molecular com-
plete remission with undetectable PML-RARa and FLT3-
ITD.
Bone marrow morphology was consistent with micro-
granular variant of APL which lacks the Auer rods and
the CD34/HLA-DR negative phenotype typically seen in
APL (Figure 1A). Microgranular APL frequently has 
FLT3-ITDs, however it does not itself predict for a worse
prognosis compared with classic APL.6
Flow cytometry was consistent with
microgranular/hypogranular variant of APL.2 The APL
blasts identified (79% total cells) were characterized by
co-expression of CD33, CD34, CD117, CD13, CD2
(dim), CD64 (dim), and were negative for expression of
HLA-DR, CD14, CD11b, CD19, CD56, and CD123
(Figure 1B). 
Cytogenetics revealed a t(15;17) rearrangement which
was subsequently confirmed by FISH as a PML-RARa
fusion in 91.5% of cells and 100% of transcripts by quan-
titative RT-PCR. A Next generation hematologic malig-
nancy panel was negative for mutations in ABL1, ASXL1,
ATM, BCOR, BIRC3, BRAF, CALR, CBL, CEBPA, CREBBP,
CSF1R, CSF3R, DNMT3A, EP300, ETV6, EZH2, FBXW7,
FGFR4, FLT3, GATA1, GATA2, GATA3, IDH1, IDH2,
IL7R, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, MPL,
NF1, NOTCH1, NOTCH2, NPM1, NRAS, NSD1, PAX5,
PDGFRA, PDGFRB, PTPN11, RUNX1, SETBP1, SF3B1,
SRSF2, STAG2, TERT, TET1, TET2, TP53, TSLP, U2AF1
and ZRSR2.4
Our patient is a unique example of APL who fortu-
itously achieved complete molecular remission with
decitabine monotherapy. She was misdiagnosed with
non-APL AML due, in part, to the lack of up-front FISH
testing for PML-RARa, nonstandard APL morphology,
and communication issues in reporting the positive cyto-
genetic findings.  Cases of microgranular variant, while
rare, have been described and highlight the importance of
cytogenetic analysis.6,7 As a result of this case, we now
have an institutional policy that all PML-RARa results
must be communicated by voice to the treating attending
physician.
Several groups have sought the role of DNA methyla-
tion in APL. DNA methyltransferase (DNMT) is the key
enzyme in DNA methylation, a process that plays a
major role in leukemogenesis.8 Di Croce et al., have sug-
gested that the PML-RARa fusion protein interacts with
DNMT1 and DNMT3A, leading to hyper-methylation
and subsequent silencing of downstream pathways
involved in hematopoietic cell differentiation - such as
RARa.8 Furthermore, overexpression of DNMT3A, in col-
laboration with PML-RARa, promotes APL leukemogen-
esis in vivo. While ATRA can make changes in posttrans-
lational modification such as histone acetylation, it does
not affect DNA methylation in APL cells.9 Therefore,
there may be a role for hypomethylating agents in com-
bination with ATRA and ATO to improve therapeutic
outcomes of APL through activity in an additional path-
way.
Decitabine is a well-tolerated hypomethylating agent
that alters gene expression resulting in several
antileukemic effects. Forkhead box (FOX) genes are impor-
tant in hematopoietic cell differentiation. FOXC1 tran-
scription levels are low in APL, in contrast to AML.10
Interestingly, in APL cell lines, decitabine upregulates
FOXC1 transcription to normal levels through
hypomethylation of the promoter,10,11 which may pro-
mote differentiation. Furthermore, decitabine can acti-
vate the TRAIL pathway in APL cells, thus inducing
leukemic cell apoptosis.12 Finally, decitabine has been
shown to induce apoptosis in the ATRA resistant APL cell
line NB4-R213 as well as HL-60 acute myeloid leukemia
cells.14
Further support of the role of hypomethylating agents
is provided by a case of refractory APL with variant
translocation STAT5B/RARA where decitabine was used
in combination with alternating cycles of
idarubicin/cytarabine and aclacinomycin/cytarabine
inducing a complete and durable response.15 
Although this patient presented with a low WBC CT
and low-risk APL clinical features, she harbored the
FLT3-ITD mutation which some view as an added risk
factor in acute myeloid leukemia. Her robust molecular
response after decitabine single agent therapy is remark-
able. She continues in complete remission 24 months
after standard consolidation with ATRA and ATO. This
case has prompted us to consider the addition of
decitabine to ATRA and ATO induction as an attractive
alternative to anthracyclines in high-risk APL. 
Our elderly patient with low-risk APL achieved com-
plete morphologic and molecular remission after single
agent treatment with decitabine. 
In cases of high-risk APL, where many centers use
cytotoxic chemotherapy, decitabine may be an effica-
cious and more tolerable alternative to anthracycline
therapy.
Our case is the first to demonstrate the potential effica-
cy of front-line single-agent decitabine in a patient with
de novo APL, with the potential caveated that the APL did
not have a classic morphology and expressed CD34.
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